共 50 条
- [31] Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial[J]. VACCINE, 2010, 28 (03) : 840 - 848Keitel, WendyGroth, NicolaLattanzi, MariaPraus, MichaelaHilbert, Anne KatrinBorkowski, AstridTsai, Ted F.
- [32] Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial[J]. ECLINICALMEDICINE, 2022, 45Pitisuttithum, PunneeLuvira, ViravarnLawpoolsri, SaranathMuangnoicharoen, SantKamolratanakul, SupitchaSivakorn, ChaisithNarakorn, PiengthongSurichan, SomchaiyaPrangpratanporn, SumaleePuksuriwong, SuttidaLamola, StevenMercer, Laina D.Raghunandan, RamaSun, WeinaLiu, YonghongCarreno, Juan ManuelScharf, RamiPhumratanaprapin, WeerapongAmanat, FatimaGagnon, LucHsieh, Ching-LinKaweepornpoj, RuangchaiKhan, SarwatLal, ManjariMcCroskery, StephenMcLellan, JasonMena, IgnacioMeseck, MarciaPhonrat, BenjaluckSabmee, YupaSingchareon, RatsamikornSlamanig, StefanSuthepakul, NavaTcheou, JohnstoneThantamnu, NarumonTheerasurakarn, SomponeTran, StevenVilasmongkolchai, ThanakritWhite, Jessica A.Bhardwaj, NinaGarcia-Sastre, AdolfoPalese, PeterKrammer, FlorianPoopipatpol, KittisakWirachwong, PonthipHjorth, RichardInnis, Bruce L.
- [33] Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial[J]. LANCET INFECTIOUS DISEASES, 2021, 21 (12): : 1645 - 1653Han, BihuaSong, YufeiLi, ChangguiYang, WanqiMa, QingxiaJiang, ZhiweiLi, MinjieLian, XiaojuanJiao, WenbinWang, LeiShu, QunWu, ZhiweiZhao, YuliangLi, QiGao, Qiang
- [34] Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase 2162; randomized clinical trial in adults[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 710 - 716Song, Joon YoungLee, JacobWoo, Heung JeongWie, Seong-HeonLee, Jin SooKim, Shin WooKim, Tae HyongJung, Sook-InNoh, Ji YunChoi, Won SukCheong, Hee JinKim, Woo Joo
- [35] Safety, immunogenicity, and clinical response of a survivin-based peptide vaccine in therapy-resistant advanced cancer: Results from a phase I/II trial[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Becker, J. C.Wobser, M.Hofmeister, V.Bauer, B.Broecker, E. B.Straten, P. ThorAndersen, M. H.
- [36] Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial[J]. VACCINE, 2015, 33 (41) : 5437 - 5444Song, Joon YoungCheong, Hee JinLee, JacobWoo, Heung JeongWie, Seong-HeonLee, Jin-SooKim, Shin WooNoh, Ji YunChoi, Won SukKim, HunKim, Kyung-HoKim, Woo Joo
- [37] Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults[J]. JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (03): : e647 - e656Shaw, Christine A.Essink, BrandonHarper, CharlesMithani, RunaKapoor, ArchanaDhar, RakeshWilson, LaurenGuo, RuitingPanozzo, Catherine A.Wilson, EleanorSimorellis, Alana K.Reuter, CarolineStoszek, Sonia K.Chen, Grace L.Das, RituparnaGoswami, Jaya
- [38] Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam[J]. VACCINE, 2022, 40 (26) : 3621 - 3632Anh Duc DangThiem Dinh VuHa Hai VuVan Thanh TaAnh Thi Van PhamMai Thi Ngoc DangBe Van LeThai Huu DuongDuoc Van NguyenLawpoolsri, SaranathChinwangso, PailinrutMcLellan, Jason S.Hsieh, Ching-LinGarcia-Sastre, AdolfoPalese, PeterSun, WeinaMartinez, Jose L.Gonzalez-Dominguez, IreneSlamanig, StefanCarreno, Juan ManuelTcheou, JohnstoneKrammer, FlorianRaskin, ArielHuong Minh VuThang Cong TranHuong Mai NguyenMercer, Laina D.Raghunandan, RamaLal, ManjariWhite, Jessica A.Hjorth, RichardInnis, Bruce L.Scharf, Rami
- [39] Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial[J]. LANCET INFECTIOUS DISEASES, 2023, 23 (08): : 956 - 964Jenkin, DanielWright, DanielFolegatti, Pedro M.Platt, AbigailPoulton, IanLawrie, AlisonTran, NguyenBoyd, AmyTurner, CherylGitonga, John N.Karanja, Henry K.Mugo, DaisyEwer, Katie J.Bowden, Thomas A.Gilbert, Sarah C.Charleston, BryanKaleebu, PontianoHill, Adrian V. S.Warimwe, George M.
- [40] Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials[J]. LANCET, 2018, 391 (10120): : 563 - 571Modjarrad, KayvonLin, LeyiGeorge, Sarah L.Stephenson, Kathryn E.Eckels, Kenneth H.De La Barrera, Rafael A.Jarman, Richard G.Sondergaard, EricaTennant, JaniceAnsel, Jessica L.Mills, KristinKoren, MichaelRobb, Merlin L.Barrett, JillThompson, JasonKosel, Alison E.Dawson, PeterHale, AndrewTan, C. SabrinaWalsh, Stephen R.Meyer, Keith E.Brien, JamesCrowell, Trevor A.Blazevic, AzraMosby, KarlaLarocca, Rafael A.Abbink, PeterBoyd, MichaelBricault, Christine A.Seaman, Michael S.Basil, AnneWalsh, MelissaTonwe, VeronicaHoft, Daniel F.Thomas, Stephen J.Barouch, Dan H.Michael, Nelson L.